Fujifilm Holdings Corporation is to accelerate the development of the Alzheimer’s Disease drug “T-817MA” following the commencement of a Phase II clinical trial in late May by its group company, Toyama Chemical, in Japan. In the United States, Fujifilm Corporation entered into a partnership with …

READ FULL ARTICLE Curated publisher From Medical Express